Skip to content
Vivo logo
← All articles

Clinicians: Tirzepatide vs Semaglutide, SURMOUNT-5 and Compounding

Clinicians: Tirzepatide vs Semaglutide, SURMOUNT-5 and Compounding

Abstract comparison of two treatment pathways

In head-to-head trials and pooled analyses, tirzepatide typically produces greater weight loss and somewhat larger A1C reductions than semaglutide. Both drugs carry similar gastrointestinal side effects and the same boxed warning for thyroid C-cell tumors. Individual suitability still depends on health history, tolerability, and the judgment of a licensed provider.

TL;DR:

  • Tirzepatide generally results in greater weight loss, reaching up to 20% of body weight in trials, compared to 6%-14% for semaglutide; higher doses increase both efficacy and GI side effects.
  • Both drugs lower A1C effectively, with tirzepatide showing a modest advantage in glycemic reduction in direct comparison trials.
  • The most common adverse effects are gastrointestinal, especially during dose escalation, and both carry a boxed warning for thyroid C-cell tumors, with contraindications for personal or family history of medullary thyroid carcinoma.
  • Cost and insurance coverage often favor semaglutide for diabetes, but compounded formulations of both drugs are frequently used to improve access, though efficacy data mainly apply to the branded versions.
  • Long-term adherence can be challenging due to early GI side effects, dose titration schedules, and costs, making provider follow-up essential in supporting sustained treatment.
Vivo ClinicExplore Supervised Tirzepatide CareVivo Clinic offers personalized, provider-supervised tirzepatide treatment with precision-compounded therapies delivered directly to your door.Visit Vivo Clinic

Table of Contents

Tirzepatide and semaglutide at a glance

Tirzepatide and semaglutide belong to the same broad drug class but work through different receptor targets, and that distinction shows up in both their efficacy data and their prescribing considerations.

  • Mechanism: semaglutide activates the GLP-1 receptor alone; tirzepatide activates both the GIP and GLP-1 receptors. Both are administered once weekly by subcutaneous injection.
  • Weight loss range: trial data put semaglutide’s weight loss in the range of roughly 6% to 14% of body weight depending on dose and population, while tirzepatide trials report weight loss reaching about 20% at maximum tolerated doses, as detailed in the SURMOUNT-5 trial.
  • Glycemic control: both lower A1C meaningfully in type 2 diabetes, with tirzepatide showing a modest edge in head-to-head comparison.
  • Boxed warning: both labels carry a warning for rodent thyroid C-cell tumors and list personal or family history of medullary thyroid carcinoma or MEN2 as a contraindication.
  • Common side effects: nausea, diarrhea, and vomiting are the most frequently reported adverse events for both drugs, concentrated during dose escalation.
  • Hypoglycemia risk: rises for both agents when combined with insulin or sulfonylureas, requiring closer glucose monitoring.

Trial evidence: how tirzepatide and semaglutide compare head-to-head

The clearest answer to how these two drugs stack up comes from trials that put them against each other directly, rather than against placebo.

The SURPASS-2 trial, published in the New England Journal of Medicine, followed adults with type 2 diabetes for 40 weeks and compared tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide at 1 mg. Tirzepatide produced A1C reductions ranging from 2.01 to 2.30 percentage points across its three doses, compared with 1.86 percentage points for semaglutide.

A statistic worth noting: in SURMOUNT-5, a 72-week head-to-head trial in adults with obesity but without diabetes, tirzepatide produced a least-squares mean weight change substantially greater than semaglutide at maximum tolerated doses. That difference is one of the largest documented between two GLP-1-class drugs in direct comparison.

A broader look at the evidence confirms this pattern holds beyond these two trials:

  • A systematic review and meta-analysis pooling multiple comparative studies found a standardized mean difference of about 0.75 favoring tirzepatide, with a pooled difference of roughly 1.33 kg at six months in some analyses.
  • The same review reported high heterogeneity across included studies, with an I-squared value above 90%, meaning trial populations, doses, and follow-up periods varied considerably.
  • Dose matters: tirzepatide’s weight-loss advantage grows as the dose rises from 5 mg to 15 mg, but so does the rate of gastrointestinal adverse events and, in patients also taking insulin or secretagogues, the rate of clinically significant hypoglycemia, based on SURPASS-2 data.

These numbers describe group averages, not individual guarantees. Trial eligibility criteria exclude certain patients, dosing in a supervised trial setting does not always match real-world titration, and any single patient may respond better or worse than the reported mean. A person who tolerates semaglutide well but develops severe nausea on tirzepatide may do better, in practice, on the drug with the lower average effect size.

How tirzepatide and semaglutide work in the body

The efficacy gap between these drugs traces back to a real pharmacological difference, not just dosing strategy.

Semaglutide is a GLP-1 receptor agonist. According to its FDA prescribing information, it increases insulin secretion and lowers glucagon in a glucose-dependent manner, meaning the effect scales with how high blood glucose already is. The label also notes it causes a minor delay in gastric emptying, which contributes to appetite suppression, and that semaglutide is modified for albumin binding, extending its half-life to support once-weekly dosing.

Tirzepatide acts on both the GIP and GLP-1 receptors. Its FDA label describes a pharmacodynamic profile in which body weight reduction comes disproportionately from fat mass rather than lean mass, and notes that the gastric emptying delay is most pronounced after the first dose.

  • Semaglutide’s single-receptor action suppresses appetite and slows gastric emptying through GLP-1 pathways alone.
  • Tirzepatide’s dual-receptor action is hypothesized to produce additive or synergistic effects on appetite regulation, insulin sensitivity, and fat loss, though the exact interplay between the two receptor systems is still being studied.
  • Mechanistic reasoning helps explain why tirzepatide tends to outperform semaglutide in trials, but the trial outcomes themselves, not the biology alone, remain the primary evidence clinicians rely on.

Side effects and safety warnings for both drugs

Both drugs share a similar adverse-event profile, dominated by digestive symptoms that typically appear during the early weeks of treatment and during dose increases.

  • Nausea, diarrhea, and vomiting are the most common adverse events for both drugs. SURPASS-2 reported nausea in roughly 17% to 22% of tirzepatide patients versus about 18% for semaglutide, diarrhea in 13% to 16% versus about 12%, and vomiting in 6% to 10% versus about 8%.
  • Boxed warning: both the tirzepatide label and the semaglutide label carry a warning based on rodent studies showing thyroid C-cell tumors; both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
  • Pancreatitis and gallbladder disease: both labels flag these as potential risks requiring attention if abdominal pain develops.
  • Hypersensitivity reactions and interactions with other medications, including changes in oral drug absorption due to delayed gastric emptying, appear on both labels.
  • Hypoglycemia risk increases for both drugs when used alongside insulin or sulfonylureas, warranting closer glucose monitoring and, in some cases, a dose adjustment to the other medication.

Figure to flag: GI adverse events climb with dose in both drug classes, which is why most prescribing schedules start low and increase gradually rather than beginning at a therapeutic dose.

Patients who experience persistent vomiting, severe abdominal pain, or signs of an allergic reaction should contact their provider promptly rather than waiting for the next scheduled check-in. Mild nausea during the first few weeks of a dose increase is common and often resolves as the body adjusts.

Dosing schedules and administration for tirzepatide and semaglutide

Both drugs are given as once-weekly subcutaneous injections, and both require a gradual dose increase rather than starting at the target dose.

  • Semaglutide for type 2 diabetes typically starts at a low dose and increases over several weeks to a maintenance dose; obesity-indicated dosing follows a similar step-up pattern but allows for a higher ceiling.
  • Tirzepatide trials used doses escalating toward a maximum of 15 mg weekly, with SURPASS-2 testing 5 mg, 10 mg, and 15 mg specifically.
  • Patients taking insulin or an insulin secretagogue alongside either drug need closer glucose monitoring, since the combination raises hypoglycemia risk; the delayed gastric emptying effect of both drugs can also alter the absorption timing of oral medications.
  • Compounded formulations of tirzepatide or semaglutide differ from the FDA-approved branded products in preparation and, in some cases, concentration, which is why ongoing prescriber oversight matters regardless of which version a patient uses.

How a prescriber decides between the two

Trial data sets the ceiling on what each drug can do on average, but a prescriber’s recommendation usually comes down to a smaller set of practical factors specific to the patient in front of them.

  1. Weight-loss priority: when maximizing weight loss is the main goal and the patient tolerates GI side effects reasonably well, tirzepatide’s larger average effect size, shown in SURMOUNT-5, often makes it the first choice.
  2. Established outcomes data: some patients, particularly those with cardiovascular disease, may be steered toward semaglutide given its longer track record of outcome studies.
  3. Tolerability history: a patient who has already tried one GLP-1-class drug and tolerated or struggled with it carries useful information into the decision.
  4. Pregnancy plans: neither drug is recommended during pregnancy, and family planning timelines factor into timing.
  5. Comorbidities: kidney function, history of pancreatitis, and gallbladder disease all affect which option a provider leans toward.
  6. Cost and access: insurance coverage, out-of-pocket cost, and whether compounded access is appropriate for the patient’s situation.

Pro Tip: Bring a list of every medication and supplement you take to your prescribing appointment, since interactions with oral drugs can shift after starting either medication.

Before starting either drug, it helps to ask: What weight loss or A1C change is realistic for me specifically? How will we monitor for thyroid or pancreatic symptoms? What happens if I can’t tolerate the GI side effects? How does my insurance handle this medication? What’s the plan if progress stalls?

What Vivo Clinic offers for supervised GLP-1 therapy

Vivo Clinic specializes in provider-supervised anti-aging treatments, including NAD+ and Glutathione nasal sprays, injections, and creams, alongside compounded tirzepatide and semaglutide programs. Its broader catalog includes Sermorelin and MIC+B12, all prepared by licensed compounding pharmacies rather than manufactured as mass-market branded products.

  • The treatment selection process is guided, meaning a licensed provider reviews a patient’s history before recommending a specific therapy or dose.
  • Data handling follows HIPAA-compliant practices, a baseline expectation for telehealth services managing prescription records.
  • Dedicated product pages, including the compounded semaglutide page, detail dosing options and how prescriptions are supervised from intake through delivery.
  • Compounded formulations are prepared to order and may differ from the exact branded products studied in key trials, so patients should understand that trial outcomes describe the branded versions specifically and ask their provider how that distinction applies to their own treatment plan.

Cost and insurance coverage for tirzepatide and semaglutide

Insurance coverage for both drugs depends heavily on diagnosis code. Plans are far more likely to cover either medication when prescribed for type 2 diabetes than when prescribed for weight loss alone, since many insurers still classify weight-loss indications separately from diabetes indications, even when the underlying drug is identical.

Out-of-pocket costs for the branded versions of either drug can be substantial without coverage, which is part of why compounded alternatives, prepared by licensed pharmacies under prescriber supervision, have become a common access route for patients who do not qualify for insurance coverage or who are paying directly. Compounded pricing structures, such as a flat monthly subscription, differ from the per-fill branded pricing patients may be used to from a retail pharmacy.

Patients should confirm with their insurer whether a specific diagnosis is required for coverage and whether prior authorization applies, since requirements vary by plan and employer. A provider can also advise on whether a compounded option makes sense given a patient’s coverage situation and treatment goals.

Do patients stick with these treatments long-term?

Adherence is one of the more underreported challenges with GLP-1-class medications. Weekly injections, gradual dose titration, and GI side effects that appear early in treatment all create points where patients may pause or discontinue therapy before reaching a maintenance dose.

Discontinuation tends to cluster around two periods: the first few weeks, when nausea is most common, and later, when cost or side effect fatigue sets in. Because both tirzepatide and semaglutide require sustained use to maintain weight loss or glycemic benefit, inconsistent dosing undermines the results seen in clinical trials, which were conducted under structured follow-up and support that many real-world settings do not replicate.

Provider check-ins during the titration period, rather than a single prescription handed off without follow-up, tend to correlate with better continuation through the early side-effect window. Patients considering either drug should ask how their provider structures follow-up during the first two to three months, since that period determines whether most people stay on treatment long enough to see meaningful results.

Illustrated pathway for supervised treatment follow-up

What real-world data adds beyond the clinical trials

Clinical trials like SURPASS-2 and SURMOUNT-5 are conducted under controlled conditions with structured dosing, regular monitoring, and a patient population selected against specific eligibility criteria. Real-world use looks different: patients self-administer without the same oversight frequency, may have comorbidities that would have excluded them from a trial, and often face cost or access barriers that affect how consistently they take the medication.

This gap matters most for side-effect patterns and long-term adherence, both of which tend to look different outside a trial’s structured follow-up schedule. It also matters for compounded formulations specifically, since the SURPASS and SURMOUNT datasets describe the branded products, not compounded versions prepared by individual pharmacies. Patients using a compounded formulation are relying on the same underlying drug mechanism, but the exact efficacy and safety data generated in RCTs technically applies to the branded product studied, a distinction worth raising directly with a prescriber.

Ongoing pharmacovigilance and post-marketing surveillance continue to refine understanding of rare adverse events for both drugs, which is part of why labels for both tirzepatide and semaglutide have been updated since their original approvals.

A clinician’s lens on choosing between the two

Tirzepatide’s trial advantage is real, but it is an average, not a promise. Patients weighing cardiovascular risk history or who have already built a track record on semaglutide often have better reasons to stay the course than to chase a larger number on paper. The honest takeaway: ask what matters for your own health history, not just which drug wins on a chart. Confirm your thyroid and pancreatic history with your provider, set a realistic monitoring plan for the first three months, and treat either drug as one part of a longer-term plan that still needs nutrition and activity support behind it.

— Jack

Getting started with supervised compounded therapy

Vivo Clinic’s tirzepatide and semaglutide program is built around a telehealth intake and medical review process, not a one-time prescription handed off without follow-up. Patients complete an intake, a licensed provider reviews their history and determines whether therapy is appropriate, and if approved, a licensed U.S. compounding pharmacy prepares the prescription for delivery to the patient’s door.

  • Intake and medical history review happen through a HIPAA-compliant telehealth platform before any prescription decision.
  • A licensed provider determines suitability based on individual health history, not a generic questionnaire score.
  • Approved prescriptions are compounded by licensed U.S. pharmacies and shipped directly, with ongoing provider oversight built into the subscription.

Patients can review Vivo’s compounded tirzepatide page or compounded semaglutide page for details on each option, then speak with a licensed provider to determine which, if either, fits their health history and goals.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

How long does it take to lose 20 lbs on tirzepatide?

The exact timeline varies by starting weight, dose, and individual response, so there’s no fixed number of weeks that applies to everyone. In the SURMOUNT-5 trial, average weight loss reached about 20% of body weight by week 72 at maximum tolerated dose, which gives a general sense of pace rather than a guarantee for any individual.

Why would a doctor prescribe semaglutide instead of tirzepatide?

A provider may prefer semaglutide when a patient has established cardiovascular disease, given its longer track record of outcome data, or when a patient has already tolerated semaglutide well in the past. Cost, insurance coverage, and personal tolerability also factor into the decision.

What is the bad side of tirzepatide?

The most common adverse effects are gastrointestinal, including nausea, diarrhea, and vomiting, which tend to appear during dose escalation. Tirzepatide also carries a boxed warning for thyroid C-cell tumors seen in rodent studies, per its FDA label, and is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2.

Why does semaglutide work for me but not tirzepatide?

Individual response to either drug varies widely regardless of trial averages, since factors like metabolism, tolerability, and how consistently a dose schedule is followed all influence outcomes. A person who tolerates semaglutide’s side-effect profile better may stay on an effective dose longer and see better results than they would on a drug they can’t tolerate at a higher dose.

Sources